SG11201809902QA - Functional prediction of cellular functions by means of microrna expression profiling in mesenchymal stem cells - Google Patents

Functional prediction of cellular functions by means of microrna expression profiling in mesenchymal stem cells

Info

Publication number
SG11201809902QA
SG11201809902QA SG11201809902QA SG11201809902QA SG11201809902QA SG 11201809902Q A SG11201809902Q A SG 11201809902QA SG 11201809902Q A SG11201809902Q A SG 11201809902QA SG 11201809902Q A SG11201809902Q A SG 11201809902QA SG 11201809902Q A SG11201809902Q A SG 11201809902QA
Authority
SG
Singapore
Prior art keywords
scotland
sistemic
osp
glasgow
campus
Prior art date
Application number
SG11201809902QA
Inventor
David Mallinson
Donald Dunbar
Elaine Gourlay
Daria Olijnyk
James Reid
Original Assignee
Sistemic Scotland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1608086.3A external-priority patent/GB2550139B/en
Priority claimed from GB1608081.4A external-priority patent/GB2550136A/en
Priority claimed from GBGB1608497.2A external-priority patent/GB201608497D0/en
Application filed by Sistemic Scotland Ltd filed Critical Sistemic Scotland Ltd
Publication of SG11201809902QA publication Critical patent/SG11201809902QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111101011111111111 01110111110111111111111111101111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/194561 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) kind of regional protection available): ARIPO (BW, GH, (21) International Application Number: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, PCT/EP2017/061096 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (22) International Filing Date: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 09 May 2017 (09.05.2017) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (25) Filing Language: English KM, ML, MR, NE, SN, TD, TG). (26) Publication Language: English Published: (30) Priority Data: — 1608081.4 09 May 2016 (09.05.2016) GB with international search report (Art. 21(3)) 1608086.3 09 May 2016 (09.05.2016) GB 1608497.2 13 May 2016 (13.05.2016) GB (71) Applicant: SISTEMIC SCOTLAND LTD [GB/GB]; West of Scotland Science Park, Block 3, Units 3, 4 & 5, Kelvin Campus, Glasgow G20 OSP (GB). (72) Inventors: MALLINSON, David; c/o Sistemic Scotland _ Ltd, West of Scotland Science Park, Block 3, Units 3, 4 & 5, Kelvin Campus, Glasgow G20 OSP (GB). DUNBAR, Don- ald; c/o Sistemic Scotland Ltd, West of Scotland Science = Park, Block 3, Units 3, 4 & 5, Kelvin Campus, Glasgow G20 OSP (GB). GOURLAY, Elaine; c/o Sistemic Scotland = Ltd, West of Scotland Science Park, Block 3, Units 3, 4 & _ 5, Kelvin Campus, Glasgow G20 OSP (GB). OLIJNYK, = Dania; c/o Sistemic Scotland Ltd, West of Scotland Science = Park, Block 3, Units 3, 4 & 5, Kelvin Campus, Glasgow G20 _ OSP (GB). REID, James; c/o Sistemic Scotland Ltd, West of Scotland Science Park, Block 3, Units 3, 4 & 5, Kelvin Campus, Glasgow G20 OSP (GB). Agent: ELLIS, Michael; Ellis IP Ltd, 53/4 George Street, Edinburgh EH2 2HT (GB). = (74) = Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = — KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = 1-1 ,_ 1 (54) Title: FUNCTIONAL PREDICTION OF CELLULAR FUNCTIONS BY MEANS OF MICRORNA EXPRESSION PROFILING IN MESENCHYMAL STEM CELLS in 1 1' (57) : Non-coding RNA, such as miRNA, expression data derived from a cell population is used to infer the propensity of that CN cell population for a cellular functional effect for a pre-determined purpose, which effect is temporally, procedurally or interventionally 1-1 ---. separated from the cell population from which the expression data is derived. Thereby, the cellular functional effect of a cell population Ir---- can be predicted in order to improve decisions and selections to be made relating to the use of cells, e.g. from cells deriving from different 1-1 c;;;;) donors or batches, for use in bioprocess application or cell therapeutics, in order to enhance productivity, efficiency and/or efficacy. ei O
SG11201809902QA 2016-05-09 2017-05-09 Functional prediction of cellular functions by means of microrna expression profiling in mesenchymal stem cells SG11201809902QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1608086.3A GB2550139B (en) 2016-05-09 2016-05-09 Functional prediction of MSCs
GB1608081.4A GB2550136A (en) 2016-05-09 2016-05-09 Functional prediction
GBGB1608497.2A GB201608497D0 (en) 2016-05-13 2016-05-13 Functional prediction
PCT/EP2017/061096 WO2017194561A1 (en) 2016-05-09 2017-05-09 Functional prediction of cellular functions by means of microrna expression profiling in mesenchymal stem cells

Publications (1)

Publication Number Publication Date
SG11201809902QA true SG11201809902QA (en) 2018-12-28

Family

ID=58692503

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809902QA SG11201809902QA (en) 2016-05-09 2017-05-09 Functional prediction of cellular functions by means of microrna expression profiling in mesenchymal stem cells

Country Status (6)

Country Link
US (2) US11266687B2 (en)
EP (1) EP3455367A1 (en)
CA (1) CA3062963A1 (en)
IL (1) IL262884A (en)
SG (1) SG11201809902QA (en)
WO (1) WO2017194561A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014049D0 (en) * 2010-08-23 2010-10-06 Sistemic Uk Cell characterisation
ES2813407T3 (en) 2012-08-06 2021-03-23 Brainstorm Cell Therapeutics Ltd Methods to generate mesenchymal stem cells that secrete neurotrophic factors
WO2015051210A1 (en) 2013-10-03 2015-04-09 Oldcastle Architectural, Inc. Cementitious product
KR102505827B1 (en) 2014-04-10 2023-03-03 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Use of micro-ribonucleic acid(mirna) to diagnose transplant rejection and tolerance of immunosuppression therapy

Also Published As

Publication number Publication date
US11266687B2 (en) 2022-03-08
US20220160774A1 (en) 2022-05-26
US20190160101A1 (en) 2019-05-30
IL262884A (en) 2019-02-28
WO2017194561A1 (en) 2017-11-16
EP3455367A1 (en) 2019-03-20
CA3062963A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
SG11201809064QA (en) Chimeric neurotoxins
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201806398YA (en) Optimized factor viii genes
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201806395SA (en) Processor with reconfigurable algorithmic pipelined core and algorithmic matching pipelined compiler
SG11201811643TA (en) Compounds and methods for modulating rna function
SG11201907023UA (en) Method of reducing neutropenia
SG11201806853VA (en) Abstracted graphs from social relationship graph
SG11201807794VA (en) Naphthene-containing distillate stream compositions and uses thereof
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201804774YA (en) Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
SG11201809805WA (en) Three-dimensional bioreactor for cell expansion and related applications
SG11201805939QA (en) Localized temporal model forecasting
SG11201804712PA (en) Biofuel
SG11201810333UA (en) Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201804671SA (en) Aza-benzimidazole inhibitors of pad4
SG11201809413RA (en) Detection of chromosome interaction relevant to breast cancer
SG11201903329WA (en) Method for preparing electrocompetent yeast cells, and method for using said cells